Tin tức & Cập nhật

A 16-week dosing interval for the IL-23 inhibitor guselkumab appears to sufficiently keep psoriasis controlled among patients who have achieved complete skin clearance shortly after starting standard treatment with the drug, according to the phase IIIb GUIDE clinical trial.

Treatment with oral roflumilast results in reduced body weight and appetite after 24 weeks in patients with psoriasis, a study has shown.